智通财经APP获悉，基石药业-B(02616)再涨超9%，截至发稿，涨7.37%，报10.35港元，成交额2.01亿港元。
消息面上，根据香港联交所8月20日披露的文件，8月18日，新加坡政府投资公司(GIC Private Limited)增持基石药业8,040万股普通股股份，每股均价7.9港元，价值约6.35亿港元。增持后，新加坡政府投资公司最新持仓比例由0.00%升至5.49%。
国投证券发布研报称，基石药业核心品种二代IO产品PD-1/VEGF/CTLA-4三抗CS2009的全球多中心I/II期临床试验正在澳大利亚和中国积极招募患者，后续公司计划将其扩展至美国进行II期入组，预计年底前患者数将突破100例，计划于2025年下半年启动Ib/II期剂量扩展/注册性研究。此外，Ia期临床研究数据（包括安全性、PK、PD及抗肿瘤活性）将在2025年10月召开的ESMO大会上首次公布，相关数据值得期待。该行表示，考虑到公司已上市/即将上市产品的放量潜力以及丰富的临床研发管线，公司未来发展前景可观。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.